News & media

Dublin, Ireland – December 12, 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) is pleased to announce the appointment of Dominika Spilarova as its Chief Strategy Officer, effective January 10, 2025. This newly created role within Cosmo’s leadership team highlights the company’s focus on strategy-led growth and innovation. She will be reporting to the […]

Dublin, Ireland – 18 October 2024: Cosmo shareholders today approved the proposal by the Board of Directors to appoint Deloitte Accountants B.V. as new independent auditor of the Company for the financial year ending on 31 December 2024.   Cosmo’s previous auditor was appointed as independent auditor in 2016. Having given consideration to good governance […]

Dublin, Ireland – October 11, 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) is delighted to announce the appointment of Svetlana Sigalova as its new Chief Financial Officer, effective November 11, 2024. Svetlana will succeed Niall Donnelly, who has served as CFO since 2016.   Svetlana Sigalova brings a wealth of expertise from her […]

Dublin, Ireland – September 23, 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) is excited to announce the appointment of Ms. Egle Gedrimaite, as the new Head of Global Business Development, effective October 1, 2024. Egle Gedrimaite will report to Giovanni Di Napoli, CEO of Cosmo. With extensive experience in expanding global business operations […]

Dublin, Ireland – September 2, 2024: Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”), the developer and manufacturer of the GI Genius™ intelligent endoscopy system, is pleased to announce the publication of a study in “The Lancet”. This study, titled “Polyp detection with colonoscopy assisted by […]

Dublin, Ireland – 31 July 2024: Cosmo Intelligent Medical Devices (Cosmo IMD), a division of Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) focused on pioneering medical devices powered by Artificial Intelligence, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the next generation GI Genius™ hardware, the latest […]

Dublin, Ireland – 24 July 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced its 2024 half year results.   Key highlights Health Tech: Upfront payment of $100 million received from Medtronic related to expansion of AI-driven partnership; Cosmo expects to receive an additional $100m from Medtronic this year linked to new services and […]

Dublin, Ireland – 9 July 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2024 results on Wednesday, 24 July 2024 at 07:00 am CEST.   Cosmo invites investors, financial analysts and business/life science journalists to a live video webcast presentation at 2:00 pm CEST to discuss […]

Shareholders approved a dividend distribution of € 2.00 per ordinary share; representing an increase of 90% versus last year   Shareholders approved all other proposals of the Board of Directors, including the adoption of the FY2023 annual accounts and updates to the remuneration policy of the Company   Dublin, Ireland – 5 July 2024: Cosmo […]

Dublin, Ireland – 18 June 2024: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) reported that its partner and exclusive licensee of Lumeblue® (Methylene Blue MMX®) for China, China Medical System Holdings Limited (“CMS”) (SEHK: 867), has received the approval for the innovative product in the territory by the National Medical Products Administration of China […]